StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
UBS Upgrades Pfizer (PFE) to Buy, Downgrades Merck (MRK) to Neutral
December 13, 2021 9:51 AM
UBS analyst Colin Bristow downgraded shares of Merck to Neutral (NYSE: MRK) on the lack of evident catalysts and the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Hot Downgrades
Hot Upgrades
Upgrades
Next Articles
Merck's (MRK) VAXNEUVANCE Approved in the EU for Individuals 18 Years of Age and Older
December 15, 2021 6:45 AM
Pfizer (PFE) Announces FDA Approval of XELJANZ for the Treatment of Active Ankylosing Spondylitis
December 14, 2021 4:08 PM
Pfizer-BioNTech's COVID-19 Vaccine Giving 70% Protection Against Omicron, South Africa's Private Health Insurer Says
December 14, 2021 4:51 AM
Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
December 13, 2021 5:03 PM
Low Valuations to Drive Pharma M&A in 2022 - Analyst
December 13, 2021 8:50 AM
Pfizer (PFE) to Buy Arena Pharmaceuticals (ARNA) in a $6.7 Billion Deal, Pays a 100% Premium; Seen as the First of Many Acquisitions
December 13, 2021 6:41 AM
